Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
L1-79 / Yamo Pharma
NCT05067582: A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder	Completed	2	58	US	L1-79, DL-alpha-Methyltyrosine	Yamo Pharmaceuticals LLC	Autism Spectrum Disorder, Autism	06/24	06/24